• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Ethical Implications of Patient Access Restrictions


Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.

This is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA; Jessica Nance, MD, MS; Kimberly C. Chen, DO, MSHLM; Emma Ciafaloni, MD, FAAN; and Mary Pak, MD, FACP.

Haumschild engages in a discussion with Nance and Ciafaloni regarding the ethical challenges posed by patient subgroup restrictions on orphan drugs. Nance highlights the difficulties providers face when forced to deny treatment based on rigid approval criteria, emphasizing the need for flexible communication channels with decision makers. Ciafaloni emphasizes the societal responsibility to ensure equitable access to revolutionary therapies like gene therapy, urging collaborative efforts among stakeholders. The dialogue underscores the importance of open communication, involving key opinion leaders, providers, and patient advocacy groups to strike a balance between cost control and patient access. As they navigate these ethical dilemmas, the consensus emerges that prioritizing collaboration over financial considerations is paramount in ensuring fair and equitable access to life-altering treatments.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Video 10 - "Bronchiectasis Exacerbation Management"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
Video 6 - "Optimal Approaches to Diagnostic Testing for Type 1 Diabetes Mellitus"
Video 13 - "Concluding Thoughts on Ph+ ALL Treatment"
Video 12 - "The Future of Ph+ ALL Treatments"
Related Content
© 2024 MJH Life Sciences
All rights reserved.